Maria Corinna Palanca-Wessels

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 335 citations

Pharmacy, Immunology, Oncology +16

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Eric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki et al. · Blood · 2015 · 302 citations · Full text

Life Sciences, Immunology, Immunotherapy +3

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Matthias Pfeifer, Bing Zheng, Tabea Erdmann et al. · Leukemia · 2015 · 152 citations

Pharmacy, Oncology, Pharmacology +10